123 related articles for article (PubMed ID: 32660703)
1. Altered expression of TGF-β1 and TGF-βR2 in tissue samples compared to blood is associated with food habits and survival in esophageal squamous cell carcinoma.
Talukdar J; Kataki K; Ali E; Choudhury BN; Baruah MN; Bhattacharyya M; Bhattacharjee S; Medhi S
Curr Probl Cancer; 2021 Feb; 45(1):100617. PubMed ID: 32660703
[TBL] [Abstract][Full Text] [Related]
2. [Correlations between miRNAs and TGF-β1 in tumor microenvironment of esophageal squamous cell cancer].
Zhu L; Jin L; Jiang R; Wang Q; Jiang J; Mao C; Chen D
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 May; 29(5):524-8. PubMed ID: 23643275
[TBL] [Abstract][Full Text] [Related]
3. Genetic variation in transforming growth factor-beta1 gene associated with increased risk of esophageal squamous cell carcinoma.
Wei YS; Xu QQ; Wang CF; Pan Y; Liang F; Long XK
Tissue Antigens; 2007 Dec; 70(6):464-9. PubMed ID: 17990985
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of transforming growth factor beta (TGF-β) signaling axis molecules and E-cadherin in colorectal cancer.
Lampropoulos P; Zizi-Sermpetzoglou A; Rizos S; Kostakis A; Nikiteas N; Papavassiliou AG
Tumour Biol; 2012 Aug; 33(4):1005-14. PubMed ID: 22278155
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers of TGF-β signaling pathway and prognosis of pancreatic cancer.
Javle M; Li Y; Tan D; Dong X; Chang P; Kar S; Li D
PLoS One; 2014; 9(1):e85942. PubMed ID: 24465802
[TBL] [Abstract][Full Text] [Related]
6. [The association between polymorphism of transforming growth factor-β1 and radiochemotherapy response and survival in esophageal squamous cell carcinoma patients].
Zhou YL; Zhang WC; Chen XB; Xiao ZF; Qiao Y; Yu DK; Lin DX; Tan W
Zhonghua Yu Fang Yi Xue Za Zhi; 2011 Jul; 45(7):583-7. PubMed ID: 22041558
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms of transforming growth factor beta 1 (RS#1800468 and RS#1800471) and esophageal squamous cell carcinoma among Zhuangese population, China.
Tang RG; Huang YZ; Yao LM; Xiao J; Lu C; Yu Q
Gene; 2013 Jan; 512(1):1-5. PubMed ID: 23078766
[TBL] [Abstract][Full Text] [Related]
8. TGF-β1 induces epigenetic silence of TIP30 to promote tumor metastasis in esophageal carcinoma.
Bu F; Liu X; Li J; Chen S; Tong X; Ma C; Mao H; Pan F; Li X; Chen B; Xu L; Li E; Kou G; Han J; Guo S; Zhao J; Guo Y
Oncotarget; 2015 Feb; 6(4):2120-33. PubMed ID: 25544767
[TBL] [Abstract][Full Text] [Related]
9. CD82/KAI1 inhibits invasion and metastasis of esophageal squamous cell carcinoma via TGF-β1.
Zeng TD; Zheng B; Zheng W; Chen C
Eur Rev Med Pharmacol Sci; 2018 Sep; 22(18):5928-5937. PubMed ID: 30280774
[TBL] [Abstract][Full Text] [Related]
10. TGF-β1/Smad signaling pathway regulates epithelial-to-mesenchymal transition in esophageal squamous cell carcinoma: in vitro and clinical analyses of cell lines and nomadic Kazakh patients from northwest Xinjiang, China.
Pang L; Li Q; Wei C; Zou H; Li S; Cao W; He J; Zhou Y; Ju X; Lan J; Wei Y; Wang C; Zhao W; Hu J; Jia W; Qi Y; Liu F; Jiang J; Li L; Zhao J; Liang W; Xie J; Li F
PLoS One; 2014; 9(12):e112300. PubMed ID: 25464508
[TBL] [Abstract][Full Text] [Related]
11. Transforming growth factor-β1-induced epithelial-mesenchymal transition in human esophageal squamous cell carcinoma via the PTEN/PI3K signaling pathway.
Zhang HY; Wang ZQ; Li YY; Wang F; Zeng QR; Gao Y; Xuan XY; Li SS
Oncol Rep; 2014 Nov; 32(5):2134-42. PubMed ID: 25175594
[TBL] [Abstract][Full Text] [Related]
12. Serum Transforming Growth Factor-β1 Change After Neoadjuvant Chemoradiation Therapy Is Associated With Postoperative Pulmonary Complications in Esophageal Cancer Patients Undergoing Combined Modality Therapy.
Lu SL; Hsu FM; Tsai CL; Wu JK; Lee JM; Huang PM; Hsu CH; Koong AC; Chang DT; Cheng JC
Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1023-31. PubMed ID: 26475065
[TBL] [Abstract][Full Text] [Related]
13. High serum levels of vascular endothelial growth factor-A and transforming growth factor-β1 before neoadjuvant chemoradiotherapy predict poor outcomes in patients with esophageal squamous cell carcinoma receiving combined modality therapy.
Cheng JC; Graber MS; Hsu FM; Tsai CL; Castaneda L; Lee JM; Chang DT; Koong AC
Ann Surg Oncol; 2014 Jul; 21(7):2361-8. PubMed ID: 24623035
[TBL] [Abstract][Full Text] [Related]
14. ATAD2 interacts with C/EBPβ to promote esophageal squamous cell carcinoma metastasis via TGF-β1/Smad3 signaling.
Cao LJ; Zhang YJ; Dong SQ; Li XZ; Tong XT; Chen D; Wu ZY; Zheng XH; Xue WQ; Jia WH; Zhang JB
J Exp Clin Cancer Res; 2021 Mar; 40(1):109. PubMed ID: 33757572
[TBL] [Abstract][Full Text] [Related]
15. Expression of transforming growth factors in hepatocellular carcinoma and its relations with clinicopathological parameters and prognosis.
Lu Y; Wu LQ; Li CS; Wang SG; Han B
Hepatobiliary Pancreat Dis Int; 2008 Apr; 7(2):174-8. PubMed ID: 18397854
[TBL] [Abstract][Full Text] [Related]
16. TGFB1 and TGFBR2 functional polymorphisms and risk of esophageal squamous cell carcinoma: a case-control analysis in a Chinese population.
Jin G; Deng Y; Miao R; Hu Z; Zhou Y; Tan Y; Wang J; Hua Z; Ding W; Wang L; Chen W; Shen J; Wang X; Xu Y; Shen H
J Cancer Res Clin Oncol; 2008 Mar; 134(3):345-51. PubMed ID: 17680270
[TBL] [Abstract][Full Text] [Related]
17. [Expression of CD80, CD86, TGF-beta1 and IL-10 mRNA in the esophageal carcinoma].
Yang WF; Yu JM; Zuo WS; Wang SZ
Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):762-5. PubMed ID: 17366789
[TBL] [Abstract][Full Text] [Related]
18. Concordant promoter methylation of transforming growth factor-beta receptor types I and II occurs early in esophageal squamous cell carcinoma.
Dong Z; Guo W; Guo Y; Kuang G; Yang Z
Am J Med Sci; 2012 May; 343(5):375-81. PubMed ID: 22314103
[TBL] [Abstract][Full Text] [Related]
19. TGF-β-induced NKILA inhibits ESCC cell migration and invasion through NF-κB/MMP14 signaling.
Lu Z; Chen Z; Li Y; Wang J; Zhang Z; Che Y; Huang J; Sun S; Mao S; Lei Y; Gao Y; He J
J Mol Med (Berl); 2018 Apr; 96(3-4):301-313. PubMed ID: 29379981
[TBL] [Abstract][Full Text] [Related]
20. Continuous taurocholic acid exposure promotes esophageal squamous cell carcinoma progression due to reduced cell loss resulting from enhanced vascular development.
Sato S; Yamamoto H; Mukaisho K; Saito S; Hattori T; Yamamoto G; Sugihara H
PLoS One; 2014; 9(2):e88831. PubMed ID: 24551170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
